Evenity vs. Reclast

See how Evenity and Reclast compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Evenity builds new bone and slows bone loss at the same time, while Reclast (zoledronic acid) is a bisphosphonate that only slows bone breakdown.

  • Evenity is a monthly injection capped at 12 doses for life, while Reclast is an IV infusion given just once a year or once every two years.

  • Evenity carries a boxed warning for heart attack, stroke, and cardiovascular death, while Reclast's main risks are kidney problems, flu-like reactions, and jaw bone loss.

Evenity vs. Reclast Drug Summary

Evenity

Evenity (romosozumab-aqqg) is a sclerostin inhibitor, a type of monoclonal antibody that both builds new bone and slows bone breakdown. It is given as a once-monthly subcutaneous injection using two syringes and is FDA-approved for postmenopausal women at high risk for fracture. Treatment is capped at 12 monthly doses in a lifetime.

Reclast

Reclast (zoledronic acid) is a nitrogen-containing bisphosphonate that slows the natural breakdown of bone. It is given as an intravenous infusion by a healthcare provider, typically once a year for treatment or once every two years for prevention. It is FDA-approved for postmenopausal osteoporosis, men with osteoporosis, glucocorticoid-induced osteoporosis, and Paget's disease of bone.

Evenity vs. Reclast Side Effects

Evenity

Most common
Arthralgia (up to 13.1%)
Headache (≥5%)
Injection site reactions (4.9%)
Nasopharyngitis (≥2%)

Reclast

Most common
Myalgia (up to 20.4%)
Fever (up to 19.3%)
Chills (up to 18.2%)
Pain (up to 13.8%)

Evenity vs. Reclast Dosage

Evenity

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 210 mg once monthly At the start
Maximum dose 210 mg once monthly Same as starting
Dose changes None Fixed dose

Reclast

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 5 mg IV infusion At the start
Maximum dose 5 mg IV infusion Same as starting
Dose changes None Fixed dose

Evenity vs. Reclast Indications

Evenity

Evenity is FDA-approved only for osteoporosis in postmenopausal women who are at high risk for fracture, such as those with a prior fracture or multiple risk factors. It is not approved for men, premenopausal women, or women who may become pregnant.

  • Postmenopausal women at high risk for fracture

  • History of an osteoporotic fracture

  • Multiple risk factors for fracture

  • Not approved for men or premenopausal women

Reclast

Reclast covers a wider range of uses than Evenity, including treatment and prevention of osteoporosis in postmenopausal women, increasing bone mass in men, and treating glucocorticoid-induced osteoporosis. It is also FDA-approved for Paget's disease of bone in men and women.

  • Treatment and prevention of postmenopausal osteoporosis

  • Men with osteoporosis (to increase bone mass)

  • Treatment and prevention of glucocorticoid-induced osteoporosis

  • Paget's disease of bone

Evenity vs. Reclast Pros and Cons

Evenity

Evenity's ability to both build new bone and reduce bone breakdown sets it apart from bisphosphonates, but that comes with a boxed cardiovascular warning and a hard lifetime dose limit. Monthly clinic visits and a higher monthly price add to the treatment burden.

Pros

  • Only therapy that builds new bone and reduces bone breakdown at the same time

  • One monthly visit instead of daily injections used with some other bone-building drugs

  • Studied specifically in postmenopausal women at high fracture risk

Cons

  • Boxed warning for heart attack, stroke, and cardiovascular death

  • Cannot be started within a year of a heart attack or stroke

  • Capped at 12 doses in a lifetime, then a different drug is needed to keep the gains

  • Not approved for men or premenopausal women

Reclast

Reclast has decades of use and a broader label than Evenity, but it only slows bone loss rather than building new bone. Its once-yearly infusion means far fewer doses per year, though each one commonly triggers a short flu-like reaction.

Pros

  • Given as an infusion just once a year, or once every two years for prevention

  • Approved for a wider range of patients, including men, glucocorticoid-induced osteoporosis, and Paget's disease

  • No boxed cardiovascular warning

Cons

  • Common flu-like reaction (fever, muscle aches) after infusion, especially the first one

  • Cannot be used with significant kidney impairment (creatinine clearance under 35 mL/min)

  • Only slows bone breakdown; does not stimulate new bone formation like Evenity

  • Requires an in-office IV infusion of at least 15 minutes plus pre-infusion hydration and kidney checks

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.